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Abstract
In 1920s, Otto Warburg made the observation that cancer cells utilize significantly more 
glucose than normal, healthy cells, which led him to believe that cancer cells relied on 
glycolysis more than healthy cells. However, many subsequent studies have shown that 
glucose is not only necessary for glycolysis but also for oxidative phosphorylation and 
production of building blocks for the synthesis of other molecules. There are many chal-
lenges associated with studying and treating lung cancer, and there is a diverse set of 
metabolic factors influencing the tumorigenesis and metastasis of lung cancer. Lung can-
cer cells rely heavily on mitochondrial respiration, and several studies have shown that 
inhibiting mitochondrial function is an effective method to combat lung cancer. Several 
agents have been used to inhibit mitochondrial function, including cyclopamine and 
metformin. Further, more research has noted increased levels of heme flux and function 
as critical to intensified oxygen consumption and accompanying amplified pathogenesis 
and progression of lung cancer. The upregulation of mitochondrial DNA and biogenesis 
genes are also correlated with lung cancer. In this chapter, we will cover these recent and 
emerging topics in lung cancer bioenergetics research.
Keywords: heme, mitochondrial respiration, respiration genes, oxidative fuels, 
glutamine, cyclopamine
1. Introduction
Cells perform a variety of diverse functions and processes, all of which require some form of 
cellular energy. The general currency of cellular energy exists as adenosine triphosphate, a 
high energy molecule created by two main bioenergetic pathways: glycolysis and oxidative 
phosphorylation.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativeco mons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Glycolysis, which translates to “sweet splitting,” is the process of breaking down a substrate, 
usually glucose, through a series of steps to produce two ATP molecules. This process does 
not require oxygen, and it is sometimes referred to as anaerobic respiration. To begin the 
process, glucose transporters allow glucose uptake into the cell [1]. Hexokinase then phos-
phorylates glucose, which becomes glucose-6-phosphate. Glucose-6-phosphate isomerase is 
an enzyme that catalyzes the reversible isomerization of glucose-6-phosphate and fructose-
6-phosphate which follow the pentose phosphate pathway that produces nucleotides and 
NADPH, or the glycolytic pathway to make lactate. Fructose-6-phosphate undergoes a reac-
tion facilitated by phosphofructokinase-1 to become fructose-1,6 bisphosphate, which then 
becomes glyceraldehyde-3-phosphate for glycolysis or dihydroxyacetone phosphate to help 
create lipids. Glyceraldehyde-3-phosphate becomes glycerate-2-phosphate by glyceralde-
hyde-3-phosphate dehydrogenase. Glycerate-2-phosphate becomes phosphoenol pyruvate 
via enolase. To produce the two ATP of glycolysis, pyruvate kinase catalyzes the conversion of 
phosphoenol pyruvate into pyruvate (see Figure 1). Finally, pyruvate is converted to lactate, 
a process which is mediated by the enzyme lactate dehydrogenase-A. This process generates 
NAD+ from NADH. The production of NAD+ allows the process of glycolysis to be cyclical.
Figure 1. Cells use lipids, glutamine, protein, and glucose in order to gain energy. Many of these substrates, including 
those produced by glycolysis eventually lead into the tricarboxylic acid (TCA) cycle. The steps involved in ATP synthesis 
or consumption are marked in red. Those involved in utilization or production of GTP are marked in pink, while NAD+/
NADH and FAD/FADH
2
 are in blue. The numbers of ATP/GTP and NADH/FADH
2
 produced by glycolysis and by the 
tricarboxylic acid cycle are indicated.
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Oxidative phosphorylation has many more steps than glycolysis, and it requires oxygen. 
Oxidative phosphorylation creates significantly more ATP per substrate molecule than does 
glycolysis. It is a slower process, and it is made possible by mitochondrial respiratory chain 
complexes.
Mitochondria are the site of oxidative phosphorylation (see Figure 2). Mitochondria are pres-
ent in many diverse types of cells in eukaryotes, and they are capable of producing large 
quantities of energy. The respiratory chain complexes in mitochondria are responsible for 
facilitating the reactions associated with oxidative phosphorylation. Consequently, the 
unique bioenergetics of cancer suggests altered mitochondria. Indeed, some genes have been 
found to be mutated in mitochondria (see Figure 2).
The process of oxidative phosphorylation requires several protein complexes, named Complex 
I–V, all of which are partly coded by mitochondrial DNA with the exception of Complex II 
[2]. Within the inner membrane of the mitochondria, there are electron carriers that are critical 
for mitochondrial respiration. Importantly, up to 2% of electrons cycling through the electron 
transport chain can escape the process, and this creates reactive oxygen species, or ROS [3]. 
These ROS can cause significant damage to mitochondrial DNA.
Figure 2. Mitochondrial and heme function in cellular bioenergetics. Bioenergetic fuels, including glucose, glutamine, 
and fatty acids, can generate metabolites that feed into the tricarboxylic acid (TCA) cycle. Through oxidative 
phosphorylation, NADH and FADH
2
 generated from the tricarboxylic acid cycle can be used to generate a large amount 
of ATP. Heme is a central molecule in mitochondrial function and oxidative phosphorylation. Heme can be taken up 
from the extracellular space via heme transporters HRG1 and HCP1. Heme is also synthesized in mitochondria in most 
mammalian cells. Heme serves as a prosthetic group or cofactor for many enzymes in Complexes II–IV. In non-small 
cell lung cancer cells, it has been shown that heme flux and function are intensified to support enhanced oxidative 
phosphorylation.
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Pyruvate is transported into the mitochondria or transformed into lactate and nicotinamide 
adenine dinucleotide (NAD) by lactate dehydrogenase (LDH). Direct transport of pyruvate into 
the mitochondria across the outer mitochondrial membrane, intermembrane space, and inner 
mitochondrial membrane is facilitated by mitochondrial pyruvate carrier (MPC). Mitochondrial 
pyruvate carrier also facilitates the removal of hydroxide from the mitochondria. Once within 
the mitochondrial matrix, pyruvate is converted to acetyl coenzyme A (acetyl CoA) via pyruvate 
dehydrogenase catalysis. Acetyl CoA enters the tricarboxylic acid cycle, and succinate is formed 
via organic acid oxidation. NADH contains electrons that go through the electron transport chain 
(ETC), which consists of mitochondrial Complexes I–IV (see Figure 2). Complex I, alternatively 
called NADH dehydrogenase or NADH ubiquinone oxidoreductase, marks the beginning of 
the electron transport chain and is also the largest of the five mitochondrial complexes [4]. From 
Complex I, the electron transport chain brings electrons toward coenzyme Q through the inner 
mitochondrial membrane. Alternatively, electrons can skip Complex I entirely. The transport of 
these electrons is mediated by flavin-containing enzyme complexes and they also reach coenzyme 
Q via this alternative pathway [5]. From coenzyme Q, electrons are transferred to Complex III. Yet 
another pathway to coenzyme Q is possible via Complex II. Succinate is reduced and the electrons 
from the reduction of succinate are taken to coenzyme Q and Complex III. Complex III and cyto-
chrome c shift electrons to Complex IV. The movement of electrons over the inner mitochondrial 
matrix by Complexes I, III, and IV creates a proton gradient. This causes protons to enter the 
mitochondrial matrix, a process allowed by Complex V, ATP synthase (V), and causes the produc-
tion of ATP (see Figure 2). Taken together, Complexes I–V facilitate oxidative phosphorylation 
and can create up to 36 mol of ATP per mol glucose. ROS created via oxidative phosphorylation 
can be used to regenerate NAD+. It is important to note that many cancer cells prefer glutamine 
as opposed to glucose [6]. This may be because cancer mimics the effects of starvation on the 
body. During starvation, the body utilizes amino acids from a pool of amino acids, and then 
breaks down skeletal muscle to replenish the pool of amino acids. One of the major amino acids 
consumed in this process is glutamine, the very same amino acid substrate which many cancer 
cells are remarkably adept at converting for energy. Many glycolytic molecules are considerably 
upregulated in cancer, including hexokinase II, glucose transporters, pyruvate kinase, and lactate 
dehydrogenase-A [1]. These molecules serve as targets for chemotherapy drugs. In the same way, 
many oxidative phosphorylation enzymes and molecules are differentially regulated in cancer.
2. Unique clinical problems of lung cancer
Lung cancer screening with low-dose computer tomography has proven to be effective in sig-
nificantly reducing mortality of lung cancer patients through detection of nonsymptomatic 
patients at early stages [7]. These early stage patients are typically treated with surgical or radio-
logical procedures followed by periodical surveillance with radiographic imaging. Although 
these curative treatments have been successful in saving many of these patients from lung 
cancer, 30–60% of the patients are predicted to present with local or distant recurrences (mostly 
within 5 years, but some beyond the first 5 year period) [8]. This is a unique problem for lung 
cancer that limits overall survival rates in these patients to less than 60% despite early detec-
tion, as compared with greater than 95% in the case of early stage prostate or breast cancers [9]. 
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If these patients can be accurately identified at the time of initial treatment, adding appropri-
ate adjuvant therapy to their initial treatment plan may significantly increase their survival 
rates. However, adjuvant chemotherapy on Stages I–III non-small cell lung cancer (NSCLC) 
patients showed only marginal 5-year overall survival benefits of less than 6% in meta-analyses 
of recent clinical trials [10, 11]. Neither epidermal growth factor receptor-targeting therapy 
nor immunotherapy showed significant benefits in adjuvant settings for early stage NSCLC 
patients [12, 13]. Thus, no methods are currently available to effectively treat these patients. 
However, several recent experiments strongly suggest that targeting mitochondria will yield 
effective strategies to treat lung cancer patients in the future [14–18].
3. Lung cancer cells are extremely susceptible to inhibitors of 
mitochondria
Several studies have suggested that inhibiting mitochondrial function makes drug-resistant 
tumors more sensitive to treatment [14–16, 18]. When oxidative phosphorylation was suppressed, 
cancer became less able to proliferate in an anchorage-independent manner [14]. This drastically 
limits the tumorigenic capacity of cancer cells. Because mitochondria are crucial for the electron 
transport chain and therefore oxidative phosphorylation, two processes which are especially 
prominent in cancer cells, inhibiting mitochondrial function essentially starves the cancer cell of 
ATP, affecting processes such as growth and metastasis of tumors. However, because healthy 
cells have drastically lower levels of oxidative phosphorylation and often significantly lower 
energy requirements, healthy cells are not as strongly impacted as cancer cells and can maintain 
functionality. Consequently, when the mitochondria of tumor cells are tampered with to inhibit 
oxidative phosphorylation, these tumor cells become significantly more susceptible to cytotoxic 
drugs [16, 19]. Agents such as cyclopamine tartrate, a water-soluble derivative of a molecule 
found in corn lilies [20]; metformin, an antidiabetic drug [18]; BAY 87-2243, a lead structure [15]; 
and microRNA-126, a microRNA [21] have shown potential to interfere with normal mitochon-
drial function in cancer cells. These molecules interact with various aspects of mitochondrial 
function, such as interfering with Hedgehog signaling and inhibiting Complex I. Cyclopamine 
tartrate functions by inhibiting Hedgehog signaling [20]. Cyclopamine was the first chemical 
found which effectively inhibited Hedgehog signaling. Cyclopamine tartrate is an analog of 
cyclopamine, but it is more soluble in water than cyclopamine. The mechanism by which cyclo-
pamine and cyclopamine tartrate work has been studied extensively. Smoothened (SMO) is a G 
protein-coupled receptor. SMO is responsible for facilitating Hedgehog signaling. Cyclopamine 
tartrate inhibits SMO, thereby inhibiting Hedgehog signaling. In NSCLC HCC4017 cells, studies 
have demonstrated intensified oxygen consumption compared to benign HBEC cells from the 
same patient [20]. Low levels of glucose also contribute to higher oxygen consumption rates, and 
low levels of glutamine lower oxygen consumption rates. Low levels of glucose also encourage 
NSCLC cells to utilize glutamine, and low levels of glutamine contribute to increased glucose 
consumption. Although NSCLC cell lines have varying levels of sensitivity to cyclopamine tar-
trate, this agent can be used to induce apoptosis by targeting these aerobic respiration path-
ways. Further, Cyclopamine tartrate helps generate ROS, which disturb the mitochondria in 
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tumor cells. Cyclopamine tartrate can cause mitochondrial fission and fragmentation in several 
types of NSCLC cells, including H1299, A549, and H460 cells. Consequently, cyclopamine tar-
trate reduces mitochondrial respiration. Metformin has been used for years to combat Type II 
diabetes, but as of 2001, scientists were only beginning to take note of the anticancer properties 
of the drug in mammals [22]. Scientists also noticed that those individuals taking metformin 
for diabetes had lower overall rates of cancer. Recently, researchers have shed some light onto 
the mechanism of metformin. Metformin inhibits mitochondrial Complex I by reducing oxygen 
consumption in the presence of malate and pyruvate, which create NADH as a substrate for 
Complex I [23]. Metformin has also been reported to interrupt the tricarboxylic acid cycle, the 
methionine cycle, and the folate cycle, as well as decrease nucleotide synthesis.
4. Enhanced heme function is important for NSCLC cells
Heme, or iron protoporphyrin IX, is notably and inextricably linked with oxygen transport, 
storage, and utilization. Most mammalian cells can synthesize heme de novo. Many cells also 
uptake heme via heme transporters, such as HRG1 and HCP1. Heme is important for neuro-
genesis, circadian rhythm, erythroid biogenesis, and pancreatic development and functions 
as a prosthetic group for hemoglobin, myoglobin, cytochromes, peroxidases, and catalases 
[24]. Heme directly regulates transcription, cell cycle, cell death, and protein synthesis [25–
29]. When heme levels are too low or too high, therefore, many diverse processes are affected. 
There are several diseases associated with altered heme levels. These include anemia, por-
phyrias, Alzheimer’s disease, Parkinson’s disease, Type-2 diabetes, coronary heart disease, 
and several types of cancer including colorectal, pancreatic, and lung cancers [25, 30].
When levels of heme flux and function are increased, levels of oxygen utilization are also 
increased. Intensified oxygen consumption allows increased cancer cell proliferation and func-
tion [17]. Recent research suggests that non-small cell lung cancer (NSCLC) cells upregulate 
proteins that stimulate heme synthesis, uptake, and function. When these proteins abound, 
heme is significantly upregulated, and aids in lung cancer progression. Notably, affected pro-
teins include ALAS, HRG1, HCP1, cytoglobins, and cytochromes [30].
When NSCLC cells were compared to normal cells from the same patient, studies showed 
that rates of heme biosynthesis were significantly raised in cancerous cells [30]. ALAS1, a rate 
limiting enzyme in nonerythroid heme synthesis, is higher in NSCLC cells. Succinyl acetone 
has been used to lower heme levels by inhibiting heme synthesis. Succinyl acetone attacks 
delta-aminolevulinic acid dehydratase.
5. Mitochondrial respiration and biogenesis genes are upregulated in 
lung tumor cells
Lung cancer often has a genetic basis. Up to 60% of lung adenocarcinoma tissues have a driver 
mutation. These genes include Kirsten rat sarcoma viral oncogene (KRAS), epidermal growth 
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factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and proto-oncogene B-Raf (BRAF) 
[31, 32]. In lung adenocarcinoma, the type of NSCLC most frequently found to plague nonsmok-
ers, smoking causes a very different pathway of tumorigenesis [33]. In nonsmokers, there are 
four times as many differently expressed genes as in smokers [33]. This is thought to be due to 
the lung tumor locally evolving in nonsmokers. By contrast, in smokers the lung tumor is thought 
to evolve from a patch of genetically altered tissue. Furthermore, some of the genes that were 
found to be upregulated in smokers were upregulated more depending on how frequently the 
smoker smoked. Malic enzyme (ME) expression is also significantly increased in the lung tissues 
of smokers compared to nonsmokers [34]. The EGFR pathway is the most common signaling 
pathway for lung cancer, and the mutation rate of genes of the EGFR pathway reach 70–80% [32]. 
About 30–35% of lung adenocarcinoma genetic variation is attributable to the KRAS mutation. In 
NSCLC cells, 97% of KRAS mutations occur in codon 12 or 13, and by testing codon 12 for KRAS 
mutation in bronchoalveolar lavage, scientists can diagnose lung cancer. Some labs have iden-
tified proteins that are overexpressed significantly in lung adenocarcinomas. Particularly, ATP 
synthase subunit d (ATP5D) is significantly over-expressed in lung adenocarcinomas (tumor: 
n = 93, 1.155 + 0.418; normal: n = 10, 0.663 + 0.210; p value: <0.0001) [35]. Some common marker 
genes include neuron-specific enolase, carcinoembryonic antigen, cytokeratin 19 fragments 
(CYFRA 21-1), squamous cell carcinoma antigen, cancer antigen CA 125, and tissue polypeptide 
antigen, although no one marker gene is as efficient as multiple marker genes at predicting and 
diagnosing lung adenocarcinomas. Both ME and ATP-citrase lyase (ACLY) are enzymes related 
to aerobic glycolysis and fatty acid synthesis. They are both correlated with NSCLC cells, and 
ACLY tends to be more localized, whereas ME tends to signify mediastinal lymph nodes, a site 
of metastasis in the human body [34]. Interestingly, in young patients, overexpression of ACLY 
and/or ME correlated with extended survival compared to patients who did not overexpress 
ACLY and/or ME. However, in older patients, overexpression of ACLY and/or ME is predictive 
of shorter period of survival as compared to patients who do not overexpress ACLY and/or ME. 
It can therefore be inferred that potential rising treatments must take into consideration the age 
group of the afflicted patient. Mitochondrial respiration genes have also been shown to be upreg-
ulated in lung tumor cells. In lung adenocarcinoma, many genes, especially those associated with 
mitochondrial respiration, have been shown to be differently expressed than in healthy tissue 
[32]. One study noted 535 upregulated and 465 downregulated differentially expressed genes in 
lung adenocarcinoma comparing matched tissues of the same patients. One prominent class of 
upregulated genes is related to mitochondrial oxidative phosphorylation and the electron trans-
port chain. ATP5D, UQCRC2, NDUFA2, NDUFB8, NDUFA7, NDUFA1, NDUFB1, NDUFS7, 
UQCR11, NDUFV1, NDUFV2, and NDUFS3 are specifically related to bioenergetic pathways 
including mitochondrial ATP synthesis-coupled electron transport and the electron transport 
chain [32]. Additionally, genes associated with mitochondrial biogenesis are specifically upregu-
lated in circulating lung cancer cells and have been reported to be essential for their metastatic 
potential [36]. By studying metastatic cancers, LeBleu et al. investigated the role of peroxisome 
proliferator-activated receptor gamma, coactivator 1 alpha (PGC-1α) in enhancing metastatic 
potential by increasing oxygen consumption, mitochondrial biogenesis, and oxidative phosphor-
ylation rates. The effect of PGC-1α on respiration appears to be key to allowing metastasis specifi-
cally, and does not appear to strongly affect cancer cell proliferation, epithelial-to-mesenchymal 
transfer, or primary tumor growth. Activating mutations in Ras guanosine nucleotide-binding 
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proteins result in insensitivity to GTPase-activating proteins [37]. These Ras mutations are com-
mon in human cancers [38]. Activated GTP-bound Ras family members increase glucose uptake 
and flux, which partly promotes the survival and proliferation of lung cancer [37]. This effect is 
important because it increases the capacity for energy production in lung adenocarcinoma cells. 
Activated Ras also increases tricarboxylic acid cycle activity and oxygen consumption, which 
further enables cancerous cells to produce energy and therefore increases carcinogenic and met-
astatic potential of cancer cells. Cytochrome c oxidase is activated by Ras [39]. Cytochrome c 
oxidase contains 3 mitochondrial DNA–encoded and 10 genomic DNA–encoded subunits and 
forms Complex IV of the electron transport chain [40]. In some types of cancer, levels of cyto-
chrome c oxidase are significantly elevated [40, 41]. Without activated cytochrome c oxidase, 
A549 lung adenocarcinoma is incapable of growth [37]. Still more mutations in nuclear genes 
affecting mitochondrial form and function have been linked with lung cancer. Succinate dehy-
drogenase, including SDHB, SDHC, and SDHD genes, and isocitrate dehydrogenase, including 
IDH1 and IDH2 genes, code for mitochondrial components [42]. By affecting the structure of the 
mitochondria, these genes affect the function of the mitochondria, and consequently are associ-
ated with or considered causal to cancer. Due to the large genetic variation between lung tumor 
cells, or tumor heterogeneity, chemoresistance is a major problem in lung cancer treatment. Many 
chemicals which are effective on certain types of lung cancer are not effective on other types 
of lung cancer. Furthermore, individual tumors possess intratumoral heterogeneity. That is, the 
tumor has nonidentical cells. Therefore, while some cell types may respond favorably to treat-
ment, other cell types may not. Consequently, over time, these cell types begin to dominate the 
tumor and the tumor becomes chemoresistant by acquiring genetic and epigenetic changes. This 
process was first proposed by Nowell as clonal evolution [43]. Understanding tumor heterogene-
ity and variation among NSCLC categories therefore significantly increases the ability of research 
to successfully unearth potential treatments and cures for lung cancer.
6. Mitochondrial DNA is correlated with lung cancer
Mitochondrial DNA is especially susceptible to reactive oxygen species because it does not have 
protective histones and introns [44]. Further, mitochondria lack the capacity to repair damaged 
mitochondrial DNA. Consequently, mitochondrial DNA mutates more frequently than other 
genomic DNA [45]. The instability of mitochondrial DNA can have devastating effects on the cell, 
including mutations and copy number alterations [2]. Both germline and somatic mitochondrial 
DNA defects are associated with cancer. Mitochondrial DNA is thought to be able to function 
as a driver or as a complementary gene mutation of carcinogenesis according to the multiple-hit 
model, thereby allowing increased clonogenic and/or mutagenic capacities in cancer cells [2]. To 
combat these mutations, mitochondria increase their copy number drastically. Some studies sug-
gest that the number of copies of mitochondrial DNA is strongly correlated with carcinogenesis 
[44, 46]. This relationship has been supported by several other labs [47, 48]. This relationship has 
been especially noted in lung adenocarcinoma. It is important to note that some diseases have a 
causal effect with cancer, and may also increase mitochondrial DNA copy number. To overcome 
this bias due to a latent disease, mitochondrial DNA was measured in peripheral white blood 
cells. The results suggested that even in the absence of a causal disease, increased copy number 
is indicative of an increased risk of lung cancer [44]. Importantly, this connection does not hold 
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true for all types of cancer [47, 48]. Some cancers express lower mitochondrial copy numbers. 
However, in lung adenocarcinoma, the mitochondrial copy number is increased compared to 
controls. There is also a strong correlation between mitochondrial DNA copy number and TFAM 
(Transcriptional Factor A, Mitochondria) expression [48]. TFAM is a factor for transcription and 
replication and in nucleoids. TFAM binds to mitochondrial DNA. Significantly, the gene set 
responsible for controlling the tricarboxylic acid cycle and respiratory electron transport is most 
commonly correlated to copy number. In NSCLC cells, epithelial-to-mesenchymal transition is 
thought to be the critical moment defining metastatic potential [49]. It is thought that during 
epithelial-to-mesenchymal transition, the copy number of mitochondrial DNA is altered. In A549 
cells, copy number increased from 1700 to 2800 during epithelial-to-mesenchymal transition.
7. Stromal cells in the tumor microenvironment contribute bioenergetic 
molecules to cancer cells
Despite the deregulation of normal metabolic processes in tumor cells and the many contribu-
tors to mitochondrial dysfunction, tumors still have remarkable capacity to perform oxidative 
phosphorylation. This is in part due to a phenomenon where surrounding tissues contribute 
fuel sources to tumor tissues [50]. A two-compartment model was proposed in 2012 to explain 
this process [51–53]. Glycolytic stromal cells produce l-lactate and ketone bodies which are 
utilized by oxidative epithelial cancer cells. The metabolites produced by these fibroblasts 
(see Figure 3) provide fuel for cancer proliferation via oxidative phosphorylation [54]. This 
process is thought to be mediated by pyruvate kinase isoforms. Glutamine helps to fuel this 
process [55–57]. It appears as though the tumor cells take advantage of the stromal cells in a 
form of micro-level commensalism [52].
Figure 3. Metabolic fuels for tumor cells. Cancer cells use a variety of bioenergetic substrates including glucose, 
glutamine, fatty acids, and ketones. Stromal cells in the tumor microenvironment can provide various oxidative fuels 
depending on their characteristics. Shown here are adipocytes and fibroblasts.
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8. Summary
Emerging evidence increasingly shows that mitochondrial respiration is key to cancer bioen-
ergetics. Particularly, heme is a central molecule in mitochondrial respiration. Many lines of 
evidence from epidemiological studies, gene expression studies of human tumor tissues, and 
molecular studies of cancer cell lines indicate that functions of heme and oxygen-utilizing 
hemoproteins are critical for tumorigenesis, particularly lung tumorigenesis. Enhanced heme 
flux and function is a key feature of non-small cell lung cancer cells. Consistent with these 
observations, many cancer cells are susceptible to inhibitors of mitochondrial function and 
heme biosynthesis. A better understanding of the relationships between mitochondrial and 
heme function with cancer bioenergetics should facilitate the development of effective strate-
gies to treat cancers, particularly lung cancer.
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